TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6206
-0.0094 (-1.4921%)
As of 3:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.6300
Open0.6200
Bid0.6201 x 1900
Ask0.6300 x 3000
Day's Range0.6101 - 0.6383
52 Week Range0.6100 - 3.3000
Volume173,251
Avg. Volume605,726
Market Cap23.65M
Beta-0.40
PE Ratio (TTM)N/A
EPS (TTM)-1.2530
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?
    Simply Wall St.5 hours ago

    What does TrovaGene Inc’s (TROV) Balance Sheet Tell Us Abouts Its Future?

    While small-cap stocks, such as TrovaGene Inc (NASDAQ:TROV) with its market cap of USD $24.01M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
    PR Newswire7 days ago

    Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075

    SAN DIEGO, Nov. 13, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with Virginia Cancer Specialists and Principal Investigator, Dr. Alexander Spira. This trial will enroll subjects in the Phase 1b who have relapsed or have resistant disease to no more than three prior regimens. The Phase 1b is a dose escalation study to determine a recommend phase 2 dose.  The Phase 2 continuation study will provide preliminary evaluation of anti-leukemic activity and will enroll newly diagnosed subjects, judged to be ineligible for, or who have refused, standard intensive induction therapy, as well as subjects who have relapsed after treatment with no more than one prior regimen.

  • Associated Press11 days ago

    Trovagene reports 3Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 12 cents. The molecular diagnostic company posted revenue of $123,000 in the period. The company's shares closed at 68 cents. A year ...

  • Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results
    PR Newswire11 days ago

    Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third ...

  • Capital Cube19 days ago

    ETFs with exposure to TrovaGene, Inc. : November 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
    PR Newswirelast month

    FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)

    SAN DIEGO, Oct. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML) on September 28, 2017. PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine Polo-like Kinase 1 (PLK1) enzyme, which appears to be over expressed in several different hematologic malignancies and solid tumor cancers.

  • When Will TrovaGene Inc (TROV) Run Out Of Cash?
    Simply Wall St.2 months ago

    When Will TrovaGene Inc (TROV) Run Out Of Cash?

    TrovaGene Inc (NASDAQ:TROV) announced a loss of -$36.81M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for TROV may beRead More...

  • Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
    PR Newswire2 months ago

    Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis

    SAN DIEGO, Sept. 20, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D. Dr. Countouriotis brings significant experience leading clinical development programs, from preclinical through clinical stages, and approval.  Over the course of her career, she has been involved in multiple clinical programs, with a focus within oncology, both hematologic and solid tumor indications, that have supported regulatory approvals in the U.S. and Europe.  Dr. Countouriotis currently serves as Senior Vice President, Chief Medical Officer at Adverum Biotechnologies.

  • What Does TrovaGene Inc’s (TROV) Share Price Indicate?
    Simply Wall St.2 months ago

    What Does TrovaGene Inc’s (TROV) Share Price Indicate?

    TrovaGene Inc (NASDAQ:TROV), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the overRead More...

  • Capital Cube3 months ago

    ETFs with exposure to TrovaGene, Inc. : September 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TrovaGene, Inc. Here are 5 ETFs with the largest exposure to TROV-US. Comparing the performance and risk of TrovaGene, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
    PR Newswire3 months ago

    Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017

    SAN DIEGO, Aug. 31, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Trovagene, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Aug. 30, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube3 months ago

    TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis TrovaGene, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of TrovaGene, Inc. – Genomic Health, Inc., Biocept, Inc., Laboratory Corporation of America Holdings, Exact Sciences Corporation, Quest Diagnostics Incorporated, PerkinElmer, Inc. and QIAGEN NV (GHDX-US, BIOC-US, LH-US, EXAS-US, DGX-US, ... Read more (Read more...)

  • Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines
    PR Newswire3 months ago

    Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines

    Additionally, Trovagene announces PCM-075 synergy in combination with more than ten chemo and targeted therapeutics across a broad range of solid tumor and hematologic malignancies SAN DIEGO , Aug. 21, ...

  • Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
    PR Newswire3 months ago

    Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy

    SAN DIEGO, Aug. 16, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from a preclinical in-vivo study examining the combination of their PLK1 inhibitor, PCM-075, with a leading investigational FLT3 Inhibitor.  This FLT3 mutant xenograft model shows PCM-075 in combination with Quizartinib resulted in 96% tumor growth inhibition versus monotherapy with Quizartinib (81%) or PCM-075 (76%).  This research data is planned for future publication. "Thirty percent of patients with AML harbor a FLT3 mutation.

  • Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results
    PR Newswire3 months ago

    Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results

    SAN DIEGO , Aug. 9, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the second quarter ended ...

  • Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute
    PR Newswire4 months ago

    Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute

    SAN DIEGO, July 28, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a precision medicine biotechnology company, today announced that Trovagene, and Antonius Schuh and Stephen Zaniboni, the company's former Chief Executive Officer and former Chief Financial Officer, have resolved their respective legal claims against each other surrounding Trovagene's termination of Dr. Schuh and Mr. Zaniboni in March 2016. Trovagene further stated that, after completing its investigation, it has come to the conclusion that Dr. Schuh and Mr. Zaniboni believed they acted at all times in a manner consistent with their duties as Trovagene officers.

  • Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia
    PR Newswire4 months ago

    Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia

    SAN DIEGO, July 27, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for PCM-075, a Polo-like Kinase 1 (PLK1) inhibitor, and has provided authorization to proceed with the treatment of patients with AML. Trovagene submitted its IND for a Phase 1b/2 clinical trial of PCM-075 in patients with AML to the FDA on June 27, 2017.

  • Accesswire4 months ago

    Trovagene, Inc. Provides Company Overview and Discusses Clinical Development Plans for PCM-075 in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / July 26, 2017 / StockNewsNow.com , The Official MicroCap News Source™, today published SNNLive Video Interview with Bill Welch, CEO of Trovagene, Inc. (NASDAQ: TROV), a precision ...

  • Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
    PR Newswire4 months ago

    Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor

    Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075's potential as safe and effective treatment for solid tumor and hematological malignancies SAN DIEGO , ...

  • Trovagene Announces $7.1 Million Registered Direct Offering
    PR Newswire4 months ago

    Trovagene Announces $7.1 Million Registered Direct Offering

    SAN DIEGO, July 14, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a precision medicine biotechnology company, today announced it has entered into a securities purchase agreement with certain accredited investors to purchase approximately $7.1 million of its common stock in a registered direct offering. The registered direct offering and concurrent private placement are expected to close on or about July 19, 2017, subject to the satisfaction of customary closing conditions.

  • Accesswire4 months ago

    Featured Company News – Trovagene Sells Its Proprietary Urine Collection And Nucleic Acid Preservation Device Nextcollect(TM) To Novogene

    Research Desk Line-up: iKang Healthcare Group Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines ...

  • Trovagene Announces Agreement with Novogene for NextCollect™ in China
    PR Newswire4 months ago

    Trovagene Announces Agreement with Novogene for NextCollect™ in China

    SAN DIEGO, July 12, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequencing capacity in the world.  Through this agreement, Novogene will purchase NextCollect™, Trovagene's proprietary urine collection and nucleic acid preservation device for validation in the Chinese market. Trovagene will sell Novogene the NextCollectTM urine collection and stabilization device, in addition to reagents and methods to extract cell-free DNA (cfDNA) from urine.

  • Trovagene, Inc. Regains Compliance with NASDAQ Listing Requirements
    PR Newswire4 months ago

    Trovagene, Inc. Regains Compliance with NASDAQ Listing Requirements

    SAN DIEGO, July 10, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a precision medicine biotechnology company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Trovagene is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.

  • Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075
    PR Newswire5 months ago

    Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075

    SAN DIEGO, July 6, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, announced today that is has formally engaged PRA Health Sciences, a leading, global contract research organization (CRO), to conduct Trovagene's Phase 1b/2 clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, in patients with acute myeloid leukemia (AML). Trovagene filed an Investigational New Drug (IND) application and protocol for PCM-075 to the FDA, and subsequently plans to initiate a Phase 1b/2 study that will assess the safety, tolerability, dose and scheduling, and preliminary efficacy of PCM-075 in patients with acute myeloid leukemia (AML).